PL2591094T3 - Sposób otrzymywania rekombinowanego adamts13 w linii komórkowej - Google Patents

Sposób otrzymywania rekombinowanego adamts13 w linii komórkowej

Info

Publication number: PL2591094T3
Authority: PL; Poland
Prior art keywords: cell culture; producing recombinant; recombinant adamts13; adamts13; producing
Prior art date: 2010-07-08

Application number

PL11738351T

Other languages

English (en)

Polish (pl)

Inventor

Leopold Grillberger

Manfred Reiter

Daniel Fleischanderl

Gregor Bramberger

Original Assignee

Baxalta GmbH

Baxalta Incorporated

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-07-08

Filing date

2011-07-08

Publication date

2019-02-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44514323&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2591094(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-07-08 Application filed by Baxalta GmbH, Baxalta Incorporated filed Critical Baxalta GmbH

2019-02-28 Publication of PL2591094T3 publication Critical patent/PL2591094T3/pl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2511/00—Cells for large scale production
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Wood Science & Technology (AREA)
Veterinary Medicine (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Biotechnology (AREA)
Hematology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
General Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Microbiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Biophysics (AREA)
Toxicology (AREA)
Cell Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Diabetes (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Analytical Chemistry (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

PL11738351T 2010-07-08 2011-07-08 Sposób otrzymywania rekombinowanego adamts13 w linii komórkowej PL2591094T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US36263510P	2010-07-08	2010-07-08
PCT/US2011/043459 WO2012006594A1 (fr)	2010-07-08	2011-07-08	Procédé de production d'adamts13 recombinant en culture cellulaire
EP11738351.3A EP2591094B1 (fr)	2010-07-08	2011-07-08	Procédé de production d'adamts13 recombinant en culture cellulaire

Publications (1)

Publication Number	Publication Date
PL2591094T3 true PL2591094T3 (pl)	2019-02-28

Family

ID=44514323

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
PL11736502T PL2590998T3 (pl)	2010-07-08	2011-07-08	SPOSÓB WYTWARZANIA REKOMBINOWANEGO vWF O DUŻEJ MASIE CZĄSTECZKOWEJ W HODOWLI KOMÓRKOWEJ
PL16153131.4T PL3064508T5 (pl)	2010-07-08	2011-07-08	Sposób wytwarzania rekombinowanego vwf o dużej masie cząsteczkowej w hodowli komórkowej
PL18175765T PL3392271T3 (pl)	2010-07-08	2011-07-08	Sposób otrzymywania rekombinowanego adamts13 w linii komórkowej
PL11738351T PL2591094T3 (pl)	2010-07-08	2011-07-08	Sposób otrzymywania rekombinowanego adamts13 w linii komórkowej

Family Applications Before (3)

Application Number	Title	Priority Date	Filing Date
PL11736502T PL2590998T3 (pl)	2010-07-08	2011-07-08	SPOSÓB WYTWARZANIA REKOMBINOWANEGO vWF O DUŻEJ MASIE CZĄSTECZKOWEJ W HODOWLI KOMÓRKOWEJ
PL16153131.4T PL3064508T5 (pl)	2010-07-08	2011-07-08	Sposób wytwarzania rekombinowanego vwf o dużej masie cząsteczkowej w hodowli komórkowej
PL18175765T PL3392271T3 (pl)	2010-07-08	2011-07-08	Sposób otrzymywania rekombinowanego adamts13 w linii komórkowej

Country Status (25)

Country	Link
US (8)	US9458222B2 (fr)
EP (6)	EP3392271B8 (fr)
JP (3)	JP5953502B2 (fr)
KR (4)	KR101924120B1 (fr)
CN (4)	CN107286235A (fr)
AU (6)	AU2011274470B2 (fr)
BR (2)	BR112013000512A2 (fr)
CA (2)	CA2805557A1 (fr)
CO (2)	CO6690745A2 (fr)
DK (3)	DK2590998T3 (fr)
EA (5)	EA035066B1 (fr)
ES (4)	ES2875772T3 (fr)
FI (1)	FI3064508T4 (fr)
HR (3)	HRP20192089T4 (fr)
HU (3)	HUE038193T2 (fr)
IL (5)	IL286298B (fr)
MX (3)	MX339632B (fr)
NZ (2)	NZ605403A (fr)
PL (4)	PL2590998T3 (fr)
PT (3)	PT2591094T (fr)
SG (3)	SG186936A1 (fr)
SI (3)	SI2590998T1 (fr)
TR (1)	TR201815211T4 (fr)
TW (4)	TWI670073B (fr)
WO (2)	WO2012006591A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2009322367B2 (en)	2008-12-05	2015-03-26	Takeda Pharmaceutical Company Limited	Methods of measuring ADAMTS13-mediated in vivo cleavage of von Willebrand factor and uses thereof
AU2010202125B1 (en)	2010-05-26	2010-09-02	Takeda Pharmaceutical Company Limited	A method to produce an immunoglobulin preparation with improved yield
US8772462B2 (en)	2010-05-26	2014-07-08	Baxter International Inc.	Removal of serine proteases by treatment with finely divided silicon dioxide
SG186936A1 (en)	2010-07-08	2013-02-28	Baxter Int	METHOD OF PRODUCING RECOMBINANT HIGH MOLECULAR WEIGHT vWF IN CELL CULTURE
HUE039317T2 (hu) *	2011-06-10	2018-12-28	Baxalta GmbH	Koagulációs betegség kezelése rekombináns VWF adagolásával
US9030963B2 (en) *	2012-12-03	2015-05-12	Honeywell International Inc.	Analyzing a network topology
UY35343A (es) *	2013-02-26	2014-09-30	Bayer Healthcare Llc	Formulaciones y procedimientos para la producción de proteína recombinante aumentada
US9677105B2 (en)	2013-03-14	2017-06-13	Momenta Pharmaceuticals, Inc.	Methods of cell culture
US8956830B2 (en)	2013-03-14	2015-02-17	Momenta Pharmaceuticals, Inc.	Methods of cell culture
US20140271622A1 (en) *	2013-03-14	2014-09-18	Momenta Pharmaceuticals, Inc.	Methods of cell culture
US9217168B2 (en)	2013-03-14	2015-12-22	Momenta Pharmaceuticals, Inc.	Methods of cell culture
AR095196A1 (es) *	2013-03-15	2015-09-30	Regeneron Pharma	Medio de cultivo celular libre de suero
AU2013203062C1 (en) *	2013-03-15	2018-06-28	Takeda Pharmaceutical Company Limited	Subcutaneous administration of adamts13
US10544231B2 (en)	2014-04-16	2020-01-28	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antibodies for the prevention or the treatment of bleeding episodes
EP3158055B1 (fr) *	2014-06-13	2019-09-11	CSL Limited	Production améliorée du facteur de von willebrand recombinant dans un bioréacteur
MA41685A (fr)	2014-10-17	2017-08-22	Biogen Ma Inc	Supplémentation en cuivre pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère
KR102794936B1 (ko) *	2015-02-05	2025-04-14	알.피.쉐러 테크놀러지즈 엘엘씨	활성화된 포르밀글리신-생성 효소 및 그것의 생산 및 사용 방법
AR104050A1 (es) *	2015-03-26	2017-06-21	Chugai Pharmaceutical Co Ltd	Proceso de producción con iones de cobre controlados
TWI870789B (zh)	2015-08-04	2025-01-21	美商再生元醫藥公司	補充牛磺酸之細胞培養基及用法
US11191818B2 (en)	2016-08-04	2021-12-07	Takeda Pharmaceutical Company Limited	Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome
CN106957815B (zh) *	2017-03-16	2021-05-07	杨涛	一种用于人类多潜能干细胞的无血清培养基的配方
EP3648787B1 (fr)	2017-07-07	2024-10-30	Takeda Pharmaceutical Company Limited	Traitement de patients atteints d'une forme grave de la maladie de von willebrand subissant une intervention chirurgicale non urgente par l'administration de vwf recombiné
ES2986574T3 (es)	2017-07-07	2024-11-12	Takeda Pharmaceuticals Co	Tratamiento de hemorragia gastrointestinal en pacientes con enfermedad de von willebrand grave mediante la administración de vwf recombinante
CA3094644A1 (fr)	2018-03-21	2019-09-26	Baxalta Incorporated	Separation de vwf et de propeptide de vwf par des procedes chromatographiques
WO2020160460A1 (fr)	2019-02-01	2020-08-06	Baxalta Incorporated	Procédés de traitement prophylactique utilisant vwf recombinant (rvwf)
US11471497B1 (en)	2019-03-13	2022-10-18	David Gordon Bermudes	Copper chelation therapeutics
US10961500B1 (en)	2019-04-23	2021-03-30	Regeneron Pharmaceuticals, Inc.	Cell culture medium for eukaryotic cells
US20220401524A1 (en)	2019-09-11	2022-12-22	Takeda Pharmaceutical Company Limited	Methods of treatment related to complexes of von willebrand factor and complement c1q
EP4037704A4 (fr)	2019-10-04	2023-04-26	The Children's Medical Center Corporation	Traitement à base d'adamts13 pour améliorer la survie de greffon
AU2021216945A1 (en)	2020-02-04	2022-09-01	Takeda Pharmaceutical Company Limited	Treatment of menorrhagia in patients with severe von Willebrand Disease by administration of recombinant VWF
JP2023526546A (ja)	2020-05-22	2023-06-21	武田薬品工業株式会社	コロナウイルス疾患の合併症の治療及び診断のための、ａｄａｍｔｓ１３組成物及び方法
JP7658302B2 (ja)	2022-03-01	2025-04-08	株式会社ダイフク	パレット洗浄乾燥機、パレット洗浄乾燥方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4767704A (en) *	1983-10-07	1988-08-30	Columbia University In The City Of New York	Protein-free culture medium
US4797368A (en)	1985-03-15	1989-01-10	The United States Of America As Represented By The Department Of Health And Human Services	Adeno-associated virus as eukaryotic expression vector
NL8500961A (nl)	1985-04-01	1986-11-03	Stichting Vrienden Van De Stic	Cdna-codering voor de humane von willebrand-factor, plasmiden met een dergelijke cdna-codering respektievelijk fragmenten ervan, alsmede micro-organismen, welke dergelijke plasmiden bevatten.
JPS62502589A (ja)	1985-04-11	1987-10-08	ザ・チヤイルドレンズ・メデイカル・センタ−・コ−ポレ−シヨン	フオン・ビルブラント因子
US5139941A (en)	1985-10-31	1992-08-18	University Of Florida Research Foundation, Inc.	AAV transduction vectors
GB9022545D0 (en)	1990-10-17	1990-11-28	Wellcome Found	Culture medium
ES2323490T3 (es)	1994-11-10	2009-07-17	Baxter Healthcare Sa	Procedimiento de produccion de agentes biologicos en un medio de cultivo sin proteinas.
DE69608668T2 (de)	1995-02-23	2001-02-01	Quest International B.V., Naarden	Peptide für gewebe- und zellkulturmedien
US6013516A (en)	1995-10-06	2000-01-11	The Salk Institute For Biological Studies	Vector and method of use for nucleic acid delivery to non-dividing cells
EP2218775B1 (fr)	1996-08-30	2015-01-28	Life Technologies Corporation	Méthode de production d'un polypeptide in vitro dans une cellule de mammifère dans un milieu de culture sans sérum and sans protéines
US6458574B1 (en) *	1996-09-12	2002-10-01	Transkaryotic Therapies, Inc.	Treatment of a α-galactosidase a deficiency
WO1998015614A1 (fr)	1996-10-10	1998-04-16	Life Technologies, Inc.	Milieux de culture de cellules animales comprenant des substances nutritives derivees de plantes
US6156570A (en)	1997-03-20	2000-12-05	Regents Of The University Of Minnesota	Process for the continuous culture of cells
US5804420A (en)	1997-04-18	1998-09-08	Bayer Corporation	Preparation of recombinant Factor VIII in a protein free medium
AT407255B (de)	1997-06-20	2001-02-26	Immuno Ag	Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
US6475725B1 (en)	1997-06-20	2002-11-05	Baxter Aktiengesellschaft	Recombinant cell clones having increased stability and methods of making and using the same
US5994136A (en)	1997-12-12	1999-11-30	Cell Genesys, Inc.	Method and means for producing high titer, safe, recombinant lentivirus vectors
US6531577B1 (en)	1997-12-15	2003-03-11	Hemasure Denmark A/S	von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
US6528286B1 (en) *	1998-05-29	2003-03-04	Genentech, Inc.	Mammalian cell culture process for producing glycoproteins
US6406909B1 (en)	1998-07-10	2002-06-18	Chugai Seiyaku Kabushiki Kaisha	Serum-free medium for culturing animal cells
AT409379B (de)	1999-06-02	2002-07-25	Baxter Ag	Medium zur protein- und serumfreien kultivierung von zellen
JP2001120262A (ja) *	1999-10-26	2001-05-08	Welfide Corp	生理活性物質の産生増強方法
US6926894B2 (en) *	2000-11-22	2005-08-09	Baxter Aktiengesellschaft	Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
JP2005517391A (ja) *	2001-11-28	2005-06-16	サンド・アクチエンゲゼルシヤフト	細胞培養方法
KR101032589B1 (ko) *	2002-01-17	2011-05-06	론자 바이올로직스 피엘씨	단백질을 생산 할 수 있으며 무글루타민 배지에서 성장할수 있는 글루타민-요구성 인간세포
US20050084828A1 (en)	2003-10-21	2005-04-21	The University Of North Carolina At Chapel Hill	Apparatus and method for braille instruction
EP1593388A1 (fr)	2004-05-05	2005-11-09	ZLB Behring GmbH	Protéines plasmatiques concentrées à usage thérapeutique comprenant du facteur de von willebrand sous forme de multimères de poids moleculaire élevé
TWI384069B (zh) *	2004-08-27	2013-02-01	Pfizer Ireland Pharmaceuticals	多胜肽之製法
US20060094104A1 (en)	2004-10-29	2006-05-04	Leopold Grillberger	Animal protein-free media for cultivation of cells
WO2006108455A1 (fr) *	2004-11-02	2006-10-19	Ares Trading S.A.	Milieu de culture pour cellules exempt de serum pour cellules mammiferes
US8273553B2 (en)	2004-11-02	2012-09-25	Ares Trading S.A.	Production of growth hormone in serum-free cell culture medium for mammalian cells
US20070049557A1 (en)	2005-08-24	2007-03-01	Hashim Ahmed	Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
DK3121266T3 (da)	2006-01-04	2020-05-11	Baxalta Inc	Oligopeptid-frie cellekulturmedier
US20070190057A1 (en)	2006-01-23	2007-08-16	Jian Wu	Methods for modulating mannose content of recombinant proteins
CN101490239A (zh) *	2006-07-14	2009-07-22	帝斯曼知识产权资产管理有限公司	改进的细胞培养方法
CA2842959A1 (fr) *	2006-09-13	2008-03-20	Abbvie Inc.	Ameliorations a la culture de cellules
US7960869B2 (en)	2006-09-22	2011-06-14	Siemens Industry, Inc.	Internal intelligence for remote operated relay
NZ577728A (en) *	2006-12-27	2012-01-12	Baxter Int	Von willebrand factor- and factor viii-polymer conjugates having a releasable linkage
PT2115126E (pt) *	2007-03-02	2015-08-24	Wyeth Llc	Utilização de cobre e glutamato na cultura de células para a produção de polipeptídeos
DE102007046611A1 (de) *	2007-09-28	2009-04-02	Osram Opto Semiconductors Gmbh	Lichtquelle mit Konversionselement und Lichtwellenleiter, Verfahren zur Herstellung der Lichtquelle und deren Verwendung
SG187397A1 (en) *	2007-12-27	2013-02-28	Baxter Int	Cell culture processes
JP5806465B2 (ja)	2007-12-31	2015-11-10	バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒＩｎｔｅｒｎａｔｉｏｎａｌＩｎｃｏｒｐ０Ｒａｔｅｄ	実質的に動物性タンパク質を含まない組換えフリンおよび実質的に動物性タンパク質を含まない組換えフリンを作製するための方法
JP4458167B2 (ja) *	2008-01-11	2010-04-28	住友金属工業株式会社	熱間塑性加工用潤滑剤を用いる継目無管製造における外面潤滑方法
WO2009116044A2 (fr)	2008-03-19	2009-09-24	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Composés pour le traitement d’infections bactériennes
EP2310523B1 (fr) *	2008-04-17	2015-06-10	Wyeth LLC	Procédés de production améliorée de protéines morphogénétiques osseuses
US8486699B2 (en) *	2008-05-23	2013-07-16	The United States Of America As Represented By The Secretary Of Agriculture	Immortal unipotent porcine PICM-19H and PICM-19B stem cell lines
US8580554B2 (en) *	2009-07-31	2013-11-12	Baxter International Inc.	Method of producing a polypeptide or virus of interest in a continuous cell culture
HUE029110T2 (en) *	2009-07-31	2017-02-28	Baxalta GmbH	Cell culture medium for ADAMTS protein expression
SG186936A1 (en)	2010-07-08	2013-02-28	Baxter Int	METHOD OF PRODUCING RECOMBINANT HIGH MOLECULAR WEIGHT vWF IN CELL CULTURE
TWI408228B (zh)	2010-10-29	2013-09-11	Univ Nat Chunghsing	用於生產一標的蛋白質的核酸建構物、重組型載體以及方法

2011
- 2011-07-08 SG SG2013000815A patent/SG186936A1/en unknown
- 2011-07-08 EP EP18175765.9A patent/EP3392271B8/fr active Active
- 2011-07-08 PL PL11736502T patent/PL2590998T3/pl unknown
- 2011-07-08 WO PCT/US2011/043455 patent/WO2012006591A1/fr active Application Filing
- 2011-07-08 PT PT11738351T patent/PT2591094T/pt unknown
- 2011-07-08 IL IL286298A patent/IL286298B/en unknown
- 2011-07-08 TW TW107130377A patent/TWI670073B/zh active
- 2011-07-08 EP EP19191438.1A patent/EP3626736A1/fr active Pending
- 2011-07-08 SI SI201131409T patent/SI2590998T1/en unknown
- 2011-07-08 KR KR1020137003278A patent/KR101924120B1/ko active Active
- 2011-07-08 HU HUE11736502A patent/HUE038193T2/hu unknown
- 2011-07-08 US US13/179,399 patent/US9458222B2/en active Active
- 2011-07-08 CN CN201710611592.4A patent/CN107286235A/zh active Pending
- 2011-07-08 TW TW100124394A patent/TWI609890B/zh active
- 2011-07-08 AU AU2011274470A patent/AU2011274470B2/en active Active
- 2011-07-08 EP EP16153131.4A patent/EP3064508B2/fr active Active
- 2011-07-08 EA EA201390080A patent/EA035066B1/ru not_active IP Right Cessation
- 2011-07-08 EP EP11738351.3A patent/EP2591094B1/fr active Active
- 2011-07-08 ES ES18175765T patent/ES2875772T3/es active Active
- 2011-07-08 PT PT161531314T patent/PT3064508T/pt unknown
- 2011-07-08 CA CA2805557A patent/CA2805557A1/fr not_active Abandoned
- 2011-07-08 HU HUE11738351A patent/HUE11738351T2/hu unknown
- 2011-07-08 TW TW105121378A patent/TWI646972B/zh active
- 2011-07-08 WO PCT/US2011/043459 patent/WO2012006594A1/fr active Application Filing
- 2011-07-08 EA EA202090067A patent/EA202090067A3/ru unknown
- 2011-07-08 KR KR1020187034201A patent/KR102027991B1/ko active Active
- 2011-07-08 EA EA201792340A patent/EA035147B1/ru not_active IP Right Cessation
- 2011-07-08 KR KR1020187024672A patent/KR102007773B1/ko active Active
- 2011-07-08 EA EA202090220A patent/EA202090220A3/ru unknown
- 2011-07-08 BR BR112013000512A patent/BR112013000512A2/pt not_active Application Discontinuation
- 2011-07-08 EP EP21170129.7A patent/EP3909977A1/fr active Pending
- 2011-07-08 JP JP2013518869A patent/JP5953502B2/ja active Active
- 2011-07-08 MX MX2013000165A patent/MX339632B/es active IP Right Grant
- 2011-07-08 PL PL16153131.4T patent/PL3064508T5/pl unknown
- 2011-07-08 DK DK11736502.3T patent/DK2590998T3/en active
- 2011-07-08 SI SI201131818T patent/SI3064508T2/sl unknown
- 2011-07-08 SI SI201131603T patent/SI2591094T1/sl unknown
- 2011-07-08 MX MX2015014216A patent/MX353409B/es unknown
- 2011-07-08 NZ NZ605403A patent/NZ605403A/en unknown
- 2011-07-08 EP EP11736502.3A patent/EP2590998B1/fr active Active
- 2011-07-08 MX MX2013000166A patent/MX2013000166A/es active IP Right Grant
- 2011-07-08 US US13/179,386 patent/US8852888B2/en active Active
- 2011-07-08 KR KR1020137003277A patent/KR101894604B1/ko active Active
- 2011-07-08 ES ES11738351.3T patent/ES2694518T3/es active Active
- 2011-07-08 NZ NZ605404A patent/NZ605404A/en unknown
- 2011-07-08 PL PL18175765T patent/PL3392271T3/pl unknown
- 2011-07-08 JP JP2013518871A patent/JP6138683B2/ja active Active
- 2011-07-08 HU HUE16153131A patent/HUE046443T2/hu unknown
- 2011-07-08 BR BR112013000515-7A patent/BR112013000515B1/pt active IP Right Grant
- 2011-07-08 CA CA2804275A patent/CA2804275A1/fr not_active Abandoned
- 2011-07-08 TW TW100124395A patent/TWI617575B/zh active
- 2011-07-08 AU AU2011274467A patent/AU2011274467B2/en active Active
- 2011-07-08 HR HRP20192089TT patent/HRP20192089T4/hr unknown
- 2011-07-08 SG SG10201809632XA patent/SG10201809632XA/en unknown
- 2011-07-08 TR TR2018/15211T patent/TR201815211T4/tr unknown
- 2011-07-08 PL PL11738351T patent/PL2591094T3/pl unknown
- 2011-07-08 PT PT117365023T patent/PT2590998T/pt unknown
- 2011-07-08 EA EA201390082A patent/EA029503B1/ru not_active IP Right Cessation
- 2011-07-08 CN CN2011800431007A patent/CN103097409A/zh active Pending
- 2011-07-08 FI FIEP16153131.4T patent/FI3064508T4/fi active
- 2011-07-08 ES ES16153131T patent/ES2761692T5/es active Active
- 2011-07-08 DK DK11738351.3T patent/DK2591094T3/en active
- 2011-07-08 DK DK16153131.4T patent/DK3064508T4/da active
- 2011-07-08 ES ES11736502.3T patent/ES2664392T3/es active Active
- 2011-07-08 CN CN2011800430945A patent/CN103097522A/zh active Pending
- 2011-07-08 CN CN201711432166.0A patent/CN108060154A/zh active Pending
- 2011-07-08 SG SG2013000799A patent/SG186935A1/en unknown
2012
- 2012-12-27 IL IL223930A patent/IL223930A/en active IP Right Grant
- 2012-12-27 IL IL223929A patent/IL223929A/en active IP Right Grant
2013
- 2013-02-07 CO CO13025488A patent/CO6690745A2/es unknown
- 2013-02-07 CO CO13025476A patent/CO6680636A2/es unknown
2014
- 2014-07-23 US US14/339,319 patent/US9409971B2/en active Active
- 2014-09-03 US US14/476,580 patent/US20150056657A1/en not_active Abandoned
2015
- 2015-07-27 AU AU2015207811A patent/AU2015207811B2/en active Active
2016
- 2016-07-01 US US15/201,125 patent/US9834591B2/en active Active
2017
- 2017-05-09 US US15/591,022 patent/US10100099B2/en active Active
- 2017-08-01 JP JP2017149409A patent/JP2017217004A/ja active Pending
- 2017-10-30 IL IL255327A patent/IL255327B/en active IP Right Grant
2018
- 2018-01-10 AU AU2018200206A patent/AU2018200206B2/en active Active
- 2018-01-24 HR HRP20180136TT patent/HRP20180136T1/hr unknown
- 2018-09-07 US US16/125,141 patent/US10822394B2/en active Active
- 2018-10-12 HR HRP20181657TT patent/HRP20181657T1/hr unknown
2020
- 2020-03-15 IL IL273304A patent/IL273304B/en unknown
- 2020-05-29 AU AU2020203565A patent/AU2020203565B2/en active Active
- 2020-10-30 US US17/086,072 patent/US11780904B2/en active Active
2022
- 2022-01-05 AU AU2022200035A patent/AU2022200035A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20210115110A1 (en)	2021-04-22
IL273304A (en)	2020-04-30
JP2017217004A (ja)	2017-12-14
AU2022200035A1 (en)	2022-01-20
BR112013000515A2 (pt)	2016-05-17
US20150056657A1 (en)	2015-02-26
CA2804275A1 (fr)	2012-01-12
KR101924120B1 (ko)	2018-11-30
US20120035110A1 (en)	2012-02-09
AU2018200206A1 (en)	2018-04-05
DK3064508T4 (da)	2023-04-11
CN103097522A (zh)	2013-05-08
KR101894604B1 (ko)	2018-09-03
CO6680636A2 (es)	2013-05-31
TW201204744A (en)	2012-02-01
EP3909977A1 (fr)	2021-11-17
KR20130091328A (ko)	2013-08-16
SG186935A1 (en)	2013-02-28
EP3392271B1 (fr)	2021-05-05
HUE046443T2 (hu)	2020-03-30
AU2011274467B2 (en)	2015-01-15
PL2590998T3 (pl)	2018-05-30
US10822394B2 (en)	2020-11-03
SI3064508T1 (sl)	2019-12-31
EP2590998B1 (fr)	2017-11-15
CN108060154A (zh)	2018-05-22
NZ605403A (en)	2014-10-31
HRP20180136T1 (hr)	2018-04-06
US9834591B2 (en)	2017-12-05
ES2761692T5 (es)	2023-07-05
EA035066B1 (ru)	2020-04-23
EP3626736A1 (fr)	2020-03-25
IL286298B (en)	2022-08-01
MX2013000165A (es)	2013-06-05
EP2590998A1 (fr)	2013-05-15
WO2012006591A1 (fr)	2012-01-12
SI2590998T1 (en)	2018-06-29
CN103097409A (zh)	2013-05-08
PT3064508T (pt)	2019-12-05
KR102007773B1 (ko)	2019-08-06
IL223930A (en)	2017-01-31
JP6284919B2 (ja)	2018-02-28
TWI617575B (zh)	2018-03-11
TWI609890B (zh)	2018-01-01
BR112013000512A2 (pt)	2016-05-17
HUE11738351T2 (hu)	2019-03-28
AU2011274470A1 (en)	2013-01-24
US20120034674A1 (en)	2012-02-09
US9409971B2 (en)	2016-08-09
EA035147B1 (ru)	2020-05-06
TW201637665A (zh)	2016-11-01
PL3392271T3 (pl)	2021-11-15
DK3064508T3 (da)	2019-11-25
JP5953502B2 (ja)	2016-07-20
HRP20192089T1 (hr)	2020-03-20
US9458222B2 (en)	2016-10-04
JP2013538046A (ja)	2013-10-10
AU2018200206B2 (en)	2020-05-28
EP3064508B1 (fr)	2019-08-28
PT2591094T (pt)	2018-11-20
AU2011274470B2 (en)	2015-08-13
HUE038193T2 (hu)	2018-09-28
ES2664392T3 (es)	2018-04-19
MX353409B (es)	2018-01-11
KR20180130587A (ko)	2018-12-07
EP3392271A1 (fr)	2018-10-24
TW201206953A (en)	2012-02-16
MX339632B (es)	2016-06-02
CN107286235A (zh)	2017-10-24
EA202090067A2 (ru)	2020-04-30
DK2591094T3 (en)	2018-11-26
US20150018525A1 (en)	2015-01-15
HRP20192089T4 (hr)	2023-04-28
PL3064508T5 (pl)	2024-04-08
AU2020203565A1 (en)	2020-06-18
IL223929A (en)	2017-11-30
AU2015207811A1 (en)	2015-08-20
EP2591094A1 (fr)	2013-05-15
JP6138683B2 (ja)	2017-05-31
EA029503B1 (ru)	2018-04-30
KR102027991B1 (ko)	2019-10-02
WO2012006594A1 (fr)	2012-01-12
SI3064508T2 (sl)	2023-05-31
AU2015207811B2 (en)	2017-10-19
IL255327B (en)	2020-04-30
EP2591094B1 (fr)	2018-09-05
DK2590998T3 (en)	2018-02-12
FI3064508T4 (fi)	2023-04-25
SG10201809632XA (en)	2018-12-28
US8852888B2 (en)	2014-10-07
SG186936A1 (en)	2013-02-28
US20180044405A1 (en)	2018-02-15
EA201390080A1 (ru)	2013-06-28
HRP20181657T1 (hr)	2019-03-08
EA202090220A3 (ru)	2020-08-31
EP3392271B8 (fr)	2021-06-16
EP3064508B2 (fr)	2023-03-15
US11780904B2 (en)	2023-10-10
TWI646972B (zh)	2019-01-11
EA202090220A2 (ru)	2020-05-31
KR20180099922A (ko)	2018-09-05
US10100099B2 (en)	2018-10-16
JP2016025873A (ja)	2016-02-12
EA202090067A3 (ru)	2020-07-31
ES2761692T3 (es)	2020-05-20
US20190085052A1 (en)	2019-03-21
AU2020203565B2 (en)	2021-09-30
TW201900207A (zh)	2019-01-01
ES2694518T3 (es)	2018-12-21
MX2013000166A (es)	2013-06-05
BR112013000515B1 (pt)	2021-11-03
EP3064508A1 (fr)	2016-09-07
EA201792340A3 (ru)	2018-07-31
NZ605404A (en)	2014-08-29
PT2590998T (pt)	2018-02-13
ES2875772T3 (es)	2021-11-11
IL286298A (en)	2021-10-31
IL273304B (en)	2021-09-30
CA2805557A1 (fr)	2012-01-12
JP2013533748A (ja)	2013-08-29
TR201815211T4 (tr)	2018-11-21
EA201390082A1 (ru)	2013-06-28
PL3064508T3 (pl)	2020-02-28
TWI670073B (zh)	2019-09-01
SI2591094T1 (sl)	2018-12-31
IL255327A0 (en)	2017-12-31
AU2011274467A1 (en)	2013-01-24
EA201792340A2 (ru)	2018-02-28
KR20130091329A (ko)	2013-08-16
CO6690745A2 (es)	2013-06-17
US20170008948A1 (en)	2017-01-12

Publication	Publication Date	Title
HRP20181657T1 (hr)	2019-03-08	Postupak proizvodnje rekombinantog adamts13 u kulturi stanica
IL267629A (en)	2019-08-29	A method for eukaryotic cell culture
HRP20182165T1 (hr)	2019-03-08	Postupak proizvodnje polipeptida ili virusa od interesa u kontinuiranoj staničnoj kulturi
HRP20190484T1 (hr)	2019-05-17	Pripravci stanične kulture i postupci proizvodnje polipeptida
GB2491209B (en)	2013-08-21	Solar cell and method for producing same
IL222454A0 (en)	2012-12-31	Improved cell cultivation process
EP2635690A4 (fr)	2013-11-27	Compositions et procédés de production de sucres fermentables
SG10201503666UA (en)	2015-06-29	Apparatus and methods for cell culture
EP2700707A4 (fr)	2014-12-03	Procédé de culture de cellules et kit de culture de cellules
GB201113641D0 (en)	2011-09-21	Cell culture support and cell culture method
EP2383331A4 (fr)	2012-06-27	Procédé de production d'un support de culture cellulaire
GB201005736D0 (en)	2010-05-19	Electrolysis cell and method of operation
IL223178A0 (en)	2013-02-03	Photovoltaic cell and method of its manufacture
GB201020075D0 (en)	2011-01-12	Mammalian cell transformation method
GB201007855D0 (en)	2010-06-23	Bioreactor for the culture of cells
GB201120446D0 (en)	2012-01-11	Mammalian cell transformation method
GB201007863D0 (en)	2010-06-23	Bioreactor for cell culture
GB201011272D0 (en)	2010-08-18	Electrochemical cell and method of operation